Congress Materials - European Academy of Dermatology and Venereology (EADV 2025)
2025 European Academy of Dermatology and Venereology | Sep 17-20 | Paris, France
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Achieving Clear or Almost-Clear Skin Clearance in Moderate-to-Severe Psoriasis is Associated With Clinically Meaningful Itch Reduction and Lower Healthcare Costs
Oluwakayode Adejoro, Amanda G. Althoff, Jing Zhao, Lawrence Rasouliyan
This poster will be available after Sep 17 2025
Baseline Characteristics of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Guselkumab Self-Administered Using the One-Press Injector in Portugal: A Study on Treatment Satisfaction
Fernando Mota, Joao Teles Sousa, Joana Antunes, Pedro Mendes-Bastos, Ana Brasileiro, Vitor Neto, Martinha Henrique, Rita Pimenta, Sofia Magina, Tiago Torres
This poster will be available after Sep 17 2025
Early Intervention With Guselkumab is Associated With Greater Efficacy and Higher Rates of Complete Skin Clearance Independent of Super Responder Status: The Phase 3b GUIDE Trial in Psoriasis
Andreas Pinter, Kilian Eyerich, Knut Schäkel, Beate Schwarz, Ralph von Kiedrowski, Felix Lauffer, Peter Weisenseel, Carle Paul, Judita Makuc, Katharine Henry, Fabian Kreimendahl, Nenja Krüger, Nikolas Spindler, Khusru Asadullah
This presentation will be available after Sep 17 2025
Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Julianty Angsana, Marta E. Polak, Sharan Nischal, Elizabeth Chen, Deepika Balakrishna, Ching-Heng Chou, Christopher Sisk, Lynn Tomsho, Arun Kannan, Cynthia DeKlotz, Megan Miller, Joseph Cafone, Paul Newbold, Betty Yang, Monica Leung, Dawn Waterworth, Nina Sabins, James G. Krueger, Andreas Pinter, Robert Bissonnette
This poster will be available after Sep 17 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield, Ricardo Galimberti, Adelaide Hebert, Wenhui Wang, Jennifer Soung, Nina Magnolo, John C. Browning, Angela Moore, Mark Lebwohl, Dagmar Wilsmann-Theis, Georgios Kokolakis, Dariusch Mortazawi, Parbeer Grewal, Megan Miller, Joseph Cafone, Shu Li, Gigi Jiang, Fabio Nunes, Cynthia DeKlotz, Amy Paller
This presentation will be available after Sep 17 2025
Efficacy of Guselkumab Through 48 Weeks in Chinese Psoriasis Patients With and Without Metabolic Comorbidities: a Post-Hoc Analysis of a Phase 4 RCT
Min Zheng, Rong Xiao, Chunlei Zhang, Furen Zhang, Qianjin Lu, Xia Li, Huiping Wang, Yuling Shi, Xiaoxue Di, Weilong Zhao, Rui Wang
This poster will be available after Sep 17 2025
Exploring Super Responders Who Remained Treatment-Free for More Than 3 Years After Guselkumab Withdrawal: Insights From the Phase 3b GUIDE Trial in Psoriasis
Knut Schäkel, Matthias Hoffmann, Michael Sebastian, Margrit Simon, Maurizio Podda, Peter Radny, Matthias Hahn, Jan C. Simon, Peter Weisenseel, Khusru Asadullah, Andreas Pinter, Carle Paul, Friedemann Taut, Judita Makuc, Nenja Krüger, Nikolas Spindler, Kilian Eyerich
This presentation will be available after Sep 17 2025
Exploring the Value of Achieving Complete or Near Complete Skin Clearance in Patients With a History of Moderate-Severe Psoriasis: A Real-World Survey in Europe
Oluwakayode Adejoro, Aaron Keal, Emily Goddard, Bruno Kranz, James Hetherington, Liane Gillespie-Akar
This poster will be available after Sep 17 2025
GUIDE Phase 3b Trial Results: Early Intervention With Guselkumab Results in Higher Rates of Fingernail Psoriasis Clearance and Maintenance of Nail Response Following Treatment Withdrawal
Knut Schäkel, Kilian Eyerich, Andreas Pinter, Peter Weisenseel, Carle Paul, Julian Wilke, Nina Trenkler, Yanqing Chen, Nikolas Spindler, Nenja Krüger, Khusru Asadullah
This poster will be available after Sep 17 2025
Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 12-month Results of the PsABIOnd Observational Study
Stefan Siebert, Mohamed Sharaf, Frank Behrens, Proton Rahman, Mitsumasa Kishimoto, Enrique R. Soriano, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Minni Koivunen, Ruben Queiro-Silva, Ennio Lubrano, Daniel Aletaha, Laure Gossec
This poster will be available after Sep 17 2025
Guselkumab Pharmacokinetics and Immunogenicity in Pediatric Psoriasis: Phase 3 PROTOSTAR Study
Vikash Sinha, Herta Crauwels, Miriam Zimmermann, Obinna N. Obianom, Bart van Hartingsveldt, Margaret Jett, Jiang Gao, An Vermeulen
This poster will be available after Sep 17 2025
Guselkumab Shows Strong Long-Term Effectiveness and High Drug Survival in Patients With Moderate-to-Severe Psoriasis Across Different Treatment Lines – First Interim Results of the Non-Interventional German G-REAL Study
Matthias Hoffmann, Knut Schäkel, Dariusch Mortazawi, Bernhard Korge, Daniela Greiner-Krüger, Marthe-Lisa Schaarschmidt, Friedmann Taut, Lukas Scharfenberger, Beate Sepanski, Nenja Krüger, Juliane Behrens, Nikolas Spindler, Ralph von Kiedrowski
This poster will be available after Sep 17 2025
High-Level Improvements in Psoriasis Area and Severity Index With Icotrokinra in Participants With Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3 ICONIC-LEAD Study
Álvaro González Cantero, Jennifer Soung, Benjamin Ehst, Joseph Cafone, Megan Miller, Shu Li, Gigi Jiang, Ya-Wen Yang, H. Chih-ho Hong, Andrew Pink
This poster will be available after Sep 17 2025
Icotrokinra Demonstrated Superior Responses Compared With Placebo and Deucravacitinib in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3 ICONIC-ADVANCE 1&2 Studies
Linda Stein Gold, April W. Armstrong, Robert Bissonnette, Nina Magnolo, Ronald B. Vender, Michael Sebastian, Maria Laura Galimberti, Athanasios Tsianakas, Marcelo Arnone, Paul Wallace, Margrit Simon, Jose Riera-Monroig, Bassey E. Edem, Jennifer Campbell, Ofelia Reyes-Servin, Lea Kephart, Yaung-Kaung Shen, Kellen Cresswell, Kim A. Papp
This poster will be available after Sep 17 2025
Icotrokinra, a Novel Targeted Oral Peptide, in Patients with Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis
Joseph F. Merola, Philip J. Mease, Laura C. Coates, Iain B. McInnes, Peter Nash, Alexis Ogdie, Lihi Eder, Mitsumasa Kishimoto, Anna Beutler, Konstantina Psachoulia, Shana Hamm, Shihong Sheng, Bei Zhou, Mehrdad Javidi, Chandni Valiathan, Charles Iaconangelo, Ya-Wen Yang, Arun Kannan, Chetan S. Karyekar, Tasneam Shagroni
This poster will be available after Sep 17 2025
Impact of Guselkumab in Real-Life on Sleep Quality Measured Using a Wearable Device in Patients With Moderate to Severe Psoriasis: Data From the CASSIOPÉE Study
Richard Marie-Aleth, Anne-Claire Fougerousse, Cristina Bulai Livideanu, Delphine Staumont Salle, Julie Baraut, Samira Chaalal, Raphaëlle Parker, Laurent Misery
This poster will be available after Sep 17 2025
Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Soumya Chakravarty, Proton Rahman, Désirée van der Heijde, Joseph F. Merola
This poster will be available after Sep 17 2025
Maintenance of Response After Guselkumab Withdrawal: Findings From an Observational Study in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
Songmei Geng, Aijun Chen, Liangdan Sun, Andrea Chen, Bin Yang
This poster will be available after Sep 17 2025
Patient Reported Impact and Satisfaction With Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: 12-month Results of the PsABIOnd Observational Study
Laure Gossec, Mohamed Sharaf, Xenofon Baraliakos, Mitsumasa Kishimoto, Ruben Queiro-Silva, Ennio Lubrano, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Christian Roux, Enrique R. Soriano, Proton Rahman, Frank Behrens, Stefan Siebert
This poster will be available after Sep 17 2025
Persistence of Guselkumab in Psoriatic Disease Over 3 Years in Real Life Conditions, a Nationwide Claims Database Analysis
Laure Gossec, Claudepierre Pascal, Constantin Arnaud, Denis Jullien, Samira Chaalal, Julie Baraut, Laure Cipiere, Gautier Laurène, Pierre Lemire, Thierry Passeron
This poster will be available after Sep 17 2025
Predictors of Psoriasis Relapse After Guselkumab Withdrawal: An Observational Analysis of Chinese Patients
Aijun Chen, Songmei Geng, Liangdan Sun, Andrea Chen, Bin Yang
This poster will be available after Sep 17 2025
Real-World Characteristics of Patients Initiating Advanced Therapy for Plaque Psoriasis in the US Specialty Dermatology Networks
Lawrence Rasouliyan, Amanda Althoff, David Wu, Nan Li, Timothy Fitzgerald, Jing Zhao
This poster will be available after Sep 17 2025
Across the Full Range of Low Body Surface Area, Moderate Psoriasis with High-Impact Site Involvement
Linda Stein Gold, Bruce Strober, April W. Armstrong, Theodore Alkousakis, Kimberly A. Papp, Richard Langley, Olivia Choi, Daphne Chan, Jenny Jeyarajah, Vlada Groysman, Mark G. Lebwohl
This poster will be available after Sep 17 2025
SPECTREM: Guselkumab Efficacy Across Multiple High-Impact Sites in Participants With Low BSA Moderate Plaque Psoriasis
Stephen K. Tyring, Angela Y. Moore, Harrison Nguyen, Nicole Seminara, Henry Yu, Theodore Alkousakis, Olivia Choi, Katelyn Rowland, Daphne Chan, Jenny Jeyarajah, Lorne Albrecht
This poster will be available after Sep 17 2025
Super-Response to Guselkumab Treatment in Chinese Patients With Moderate-to-Severe Psoriasis: a Post-Hoc Analysis From a Phase 4 RCT
Min Zheng, Kun Huang, Songmei Geng, Xiaohua Tao, Liangdan Sun, Chao Ji, Bin Yang, Yan Lu, Xiaoxue Di, Weilong Zhao, Rui Wang
This poster will be available after Sep 17 2025
Treatment of Moderate-to-Severe Psoriasis With First-Line Tumor Necrosis Factor Inhibitors or Apremilast is Associated With Fast and Frequent Treatment Failures and Greater Healthcare Resource Utilization and Costs
Oluwakayode Adejoro, Valentine Laizet, Shanti Neff-Baro
This poster will be available after Sep 17 2025
VISIBLE Cohort A: Guselkumab Demonstrated Skin Clearance and Improved Health-Related Quality of Life Through Week 48 in Participants With Moderate-to-Severe Plaque Psoriasis Across All Skin Tones
Andrew Alexis, Adrian O. Rodriguez, Geeta Yadav, Stephen K. Tyring, Olivia Choi, Theodore Alkousakis, Daphne Chan, Tony Ma, Maxwell Sauder, Javier Alonso-Llamazares, Seemal R. Desai
This poster will be available after Sep 17 2025
VISIBLE Cohort B: Guselkumab Demonstrated Scalp Clearance and Improved Health-Related Quality of Life Through Week 48 in Participants With Moderate-to-Severe Scalp Psoriasis Across All Skin Tones
Amy McMichael, Tina Bhutani, Stacy Smith, Theodore Alkousakis, Olivia Choi, Daphne Chan, Tony Ma, Ross Radusky, Jensen Yeung, George Han, Susan C. Taylor
This poster will be available after Sep 17 2025
VISIBLE: Guselkumab Impact on Psoriatic Arthritis Through Week 48 in Participants With Moderate-to-Severe Psoriasis Across All Skin Tones
Alice B. Gottlieb, Amy McMichael, Tina Bhutani, Olivia Choi, Katelyn Rowland, Theodore Alkousakis, Jessica Vasquez, Tony Ma, Soumya D. Chakravarty, Daphne Chan, Andrea Nguyen, Seemal R. Desai, Andrew Alexis, Joseph F. Merola
This poster will be available after Sep 17 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
